Nothing Special   »   [go: up one dir, main page]

WO2004030618A3 - Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines - Google Patents

Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines Download PDF

Info

Publication number
WO2004030618A3
WO2004030618A3 PCT/US2003/030156 US0330156W WO2004030618A3 WO 2004030618 A3 WO2004030618 A3 WO 2004030618A3 US 0330156 W US0330156 W US 0330156W WO 2004030618 A3 WO2004030618 A3 WO 2004030618A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
reagents
diseases
methods
disorders associated
Prior art date
Application number
PCT/US2003/030156
Other languages
French (fr)
Other versions
WO2004030618A2 (en
Inventor
Edward Roydon Jost-Price
Palaniyandi Manivasakam
Brendan Smith
Jason Fong
Benjamin A Auspitz
M James Nichols
Curtis Keith
Grant R Zimmermann
Bradley B Brasher
Noah Sachs
Todd W Chappell
Original Assignee
Combinatorx Inc
Edward Roydon Jost-Price
Palaniyandi Manivasakam
Brendan Smith
Jason Fong
Benjamin A Auspitz
M James Nichols
Curtis Keith
Grant R Zimmermann
Bradley B Brasher
Noah Sachs
Todd W Chappell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004030618(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BR0314713-4A priority Critical patent/BR0314713A/en
Priority to EP03756864A priority patent/EP1553955A4/en
Priority to AU2003299196A priority patent/AU2003299196A1/en
Priority to JP2005500317A priority patent/JP2006503905A/en
Priority to MXPA05003152A priority patent/MXPA05003152A/en
Application filed by Combinatorx Inc, Edward Roydon Jost-Price, Palaniyandi Manivasakam, Brendan Smith, Jason Fong, Benjamin A Auspitz, M James Nichols, Curtis Keith, Grant R Zimmermann, Bradley B Brasher, Noah Sachs, Todd W Chappell filed Critical Combinatorx Inc
Priority to CA002509526A priority patent/CA2509526A1/en
Publication of WO2004030618A2 publication Critical patent/WO2004030618A2/en
Priority to NO20051669A priority patent/NO20051669L/en
Publication of WO2004030618A3 publication Critical patent/WO2004030618A3/en
Priority to HR20050355A priority patent/HRP20050355A2/en
Priority to IS7811A priority patent/IS7811A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.
PCT/US2003/030156 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines WO2004030618A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002509526A CA2509526A1 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
EP03756864A EP1553955A4 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003299196A AU2003299196A1 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
JP2005500317A JP2006503905A (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of inflammatory cytokines
MXPA05003152A MXPA05003152A (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.
BR0314713-4A BR0314713A (en) 2002-09-24 2003-09-24 Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.
NO20051669A NO20051669L (en) 2002-09-24 2005-04-04 Methods and Reagents for the Treatment of Diseases and Disorders Associated with Increased Levels of Proinflammatory Cytokines
HR20050355A HRP20050355A2 (en) 2002-09-24 2005-04-19 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
IS7811A IS7811A (en) 2002-09-24 2005-04-19 Methods and test materials for the treatment of diseases and disorders associated with increased levels of inflammatory cell messengers

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US60/413,040 2002-09-24
US41726102P 2002-10-09 2002-10-09
US60/417,261 2002-10-09
US42742402P 2002-11-19 2002-11-19
US42752602P 2002-11-19 2002-11-19
US60/427,424 2002-11-19
US60/427,526 2002-11-19
US46475303P 2003-04-23 2003-04-23
US60/464,753 2003-04-23

Publications (2)

Publication Number Publication Date
WO2004030618A2 WO2004030618A2 (en) 2004-04-15
WO2004030618A3 true WO2004030618A3 (en) 2005-04-07

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/030156 WO2004030618A2 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Country Status (12)

Country Link
EP (1) EP1553955A4 (en)
JP (1) JP2006503905A (en)
AR (1) AR041386A1 (en)
AU (1) AU2003299196A1 (en)
BR (1) BR0314713A (en)
CA (1) CA2509526A1 (en)
HR (1) HRP20050355A2 (en)
IS (1) IS7811A (en)
MX (1) MXPA05003152A (en)
NO (1) NO20051669L (en)
TW (1) TW200422042A (en)
WO (1) WO2004030618A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514061A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
JP2007517766A (en) * 2003-09-24 2007-07-05 コンビナトアールエックス インコーポレーティッド Treatment for administering a combination of drugs
BRPI0511272A (en) * 2004-05-17 2007-12-04 Combinatorx Inc methods and reagents for the treatment of immunoinflammatory disorders
BRPI0517847A (en) * 2004-11-19 2008-10-21 Organon Nv combination, uses of a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist, and method for the treatment of an individual of a vertebrate species suffering from depression or a related disorder.
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
NZ562940A (en) * 2005-04-13 2010-02-26 Astion Dev As Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
JP4832806B2 (en) * 2005-06-03 2011-12-07 久光製薬株式会社 Transdermal formulation
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
CA2662535A1 (en) * 2006-09-08 2008-03-13 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
US20080064709A1 (en) * 2006-09-11 2008-03-13 Duke University Methods and compositions for the treatment of vascular depression
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
WO2010098230A1 (en) * 2009-02-27 2010-09-02 久光製薬株式会社 Transdermal preparation
PT117765A (en) * 2022-01-28 2023-07-28 Faculdade De Farmacia Da Univ De Lisboa TOPICAL FORMULATION OF FLUVOXAMINE FOR THE TREATMENT OF PSORIASIS
TW202423434A (en) * 2022-10-07 2024-06-16 瑞士商歐庫利斯營運股份有限公司 Eye drop microsuspensions of mtor inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127365A (en) * 1996-02-15 2000-10-03 Merck Sharp & Dohme Ltd. Spiro-ketal derivatives and their use as therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611302B1 (en) * 1991-10-15 2000-03-29 MULLARKEY, Michael F. Receptors for treating late phase inflammatory responses
EP0946184B1 (en) * 1996-07-15 2004-09-29 ALZA Corporation Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate
TR199902615T2 (en) * 1997-03-18 2000-03-21 Basf Aktiengesellschaft Methods and compositions for modulating the response to corticosteroids.
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127365A (en) * 1996-02-15 2000-10-03 Merck Sharp & Dohme Ltd. Spiro-ketal derivatives and their use as therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1553955A4 *

Also Published As

Publication number Publication date
IS7811A (en) 2005-04-19
AR041386A1 (en) 2005-05-18
AU2003299196A1 (en) 2004-04-23
CA2509526A1 (en) 2004-04-15
TW200422042A (en) 2004-11-01
EP1553955A2 (en) 2005-07-20
WO2004030618A2 (en) 2004-04-15
EP1553955A4 (en) 2008-11-05
JP2006503905A (en) 2006-02-02
BR0314713A (en) 2005-07-26
HRP20050355A2 (en) 2005-10-31
MXPA05003152A (en) 2006-04-27
NO20051669L (en) 2005-06-10

Similar Documents

Publication Publication Date Title
TW200509958A (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005079284A3 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005027839A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2005020972A3 (en) Combination therapy for the treatment of ocular neovascular disorders
NO20051669L (en) Methods and Reagents for the Treatment of Diseases and Disorders Associated with Increased Levels of Proinflammatory Cytokines
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
WO2004019863A3 (en) Combination therapy for treatment of fibrotic disorders
WO2006138518A8 (en) Combination therapy for the treatment of immunoinflammatory disorders
WO2003072024A3 (en) Methods of treating vascular disease
IL175781A0 (en) Methods and reagents for the treatment of inflammatory disorders
RS20050344A (en) Treatment for hemorrhagic shock
NO20062363L (en) Methods and Reagents for the Treatment of Inflammatory Disorders
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
WO2006138372A3 (en) Methods and reagents for the treatment of inflammatory disorders
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2006012603A3 (en) Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
WO2005004854A3 (en) Use of betaine for treating arteritis
WO2003099105A3 (en) Diagnosis and treatment of human dormancy syndrome
UA89753C2 (en) Use of a modafinil and an antidepressant for the treatment of depression and for decreasing the onset time of an antidepressant
WO2006063256A3 (en) Treatment using d-threo methylphenidate
EP1693062A3 (en) Androgen receptor-dependent gene expression control

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 167595

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/003152

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2005500317

Country of ref document: JP

Ref document number: 2509526

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003299196

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/02708

Country of ref document: ZA

Ref document number: 200502708

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: P20050355A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 669/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 539601

Country of ref document: NZ

Ref document number: 2003756864

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005112233

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 20038253151

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003756864

Country of ref document: EP